MirelmanA, BonatoP, CamicioliR, et al.Gait impairments in Parkinson's disease. Lancet Neurol, 2019; 18(7):697–708.
2.
LópezIC, RuizPJ, Del PozoSV, et al.Motor complications in Parkinson's disease: Ten year follow-up study. Mov Disord, 2010; 25(16):2735–2739.
3.
HelyMA, MorrisJG, ReidWG, et al.Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years. Mov Disord, 2005; 20(2):190–199.
4.
CoelhoM, MartiMJ, TolosaE, et al.Late-stage Parkinson's disease: The Barcelona and Lisbon cohort. J Neurol, 2010; 257(9):1524–1532.
PapapetropoulosS, MashDC. Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: A study from a population of brain donors. J Neural Transm (Vienna), 2007; 114(3):341–345.
7.
ChapuisS, OuchchaneL, MetzO, et al.Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord, 2005; 20(2):224–230.
BanerjeeAK, FalkaiPG, SavidgeM. Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J, 1989; 65(764):358–361.
11.
Beaulieu-BoireI, LangAE. Behavioral effects of levodopa. Mov Disord, 2015; 30(1):90–102.
12.
HiorthYH, PedersenKF, DalenI, et al.Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study. Neurology, 2019; 93(16):e1526–e1534.
13.
OhYS, LeeJE, LeePH, et al.Neuropsychiatric symptoms in Parkinson's disease dementia are associated with increased caregiver burden. J Mov Disord, 2015; 8(1):26–32.
14.
Martinez-MartinP, Rodriguez-BlazquezC, ForjazMJ, et al.Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. Parkinsonism Relat Disord, 2015; 21(6):629–634.
15.
PéchevisM, ClarkeCE, ViereggeP, et al.Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: A prospective European study. Eur J Neurol, 2005; 12(12):956–963.
